Research map: Efficacy and Hypoglycaemia Outcomes With Once‐Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1–3 Trials

Back to the article

Papers in this map

  1. A New Equation to Estimate Glomerular Filtration Rate · Andrew S. Levey · 2009 · 26117 citations · Cited by this paper
  2. IcoSema in Weight Management and Glycaemic Control: A Systematic Review and Meta-Analysis · Mahmoud Ismail Nouh · 2026 · Cites this paper
  3. Economic Impact of Multidisciplinary Pre‐operative Diabetes Care Versus Usual Care in Adults Undergoing Elective Non‐cardiac Surgery in Australia: A Trial‐Based Analysis · 2026 · Related
  4. Pathophysiology of Type 2 Diabetes Mellitus · Unai Galicia-García · 2020 · 3336 citations · Cited by this paper
  5. Feasibility of Decentralised Response‐Guided Albuminuria Monitoring to Optimise Empagliflozin and Finerenone Therapy in Type 2 Diabetes and Chronic Kidney Disease · 2026 · Related
  6. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes · Vlado Perkovic · 2024 · 1826 citations · Cited by this paper
  7. Metformin Ameliorates Diabetes‐Associated Cognitive Dysfunction via p53/Parkin‐Mediated Mitophagy · 2026 · Related
  8. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial · Melanie J. Davies · 2021 · 1389 citations · Cited by this paper
  9. Trends and Prevalence of Undiagnosed Dysglycemia Among Reproductive‐Age Women in the United States · 2026 · Related
  10. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial · CHRISTOPHER H. SORLI · 2017 · 737 citations · Cited by this paper
  11. Beyond Glycaemia: Fear of Hypoglycaemia, Cognition and Functional Mobility After Advanced Hybrid Closed‐Loop Therapy in Older Adults With Type 1 Diabetes: A Prespecified Secondary Analysis of a Randomised, Single‐Centre Study · 2026 · Related
  12. Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study · Mark F. Peyrot · 2012 · 665 citations · Cited by this paper
  13. Diagnostic Yield of Structured Cushing Syndrome Evaluation in Treatment‐Resistant Non‐Diabetic Obesity: A Retrospective Pilot Study · 2026 · Related
  14. Type 2 diabetes mellitus in adults: pathogenesis, prevention and therapy · Xi Lu · 2024 · 642 citations · Cited by this paper
  15. Exercise Snacks Are Feasible to Perform in the Real World and Improve Physical Capacity for Adults Living With Non‐Insulin Treated Type 2 Diabetes: A Randomised Trial · 2026 · Related
  16. Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial · Andrew Ahmann · 2017 · 595 citations · Cited by this paper
  17. Real‐World Effectiveness and Safety of Finerenone in People With Type 2 Diabetes and Chronic Kidney Disease: A Spanish Multicentre Retrospective Observational Study ( MEDFINE ‐ RWD ) · 2026 · Related
  18. Insulin‐associated weight gain in diabetes – causes, effects and coping strategies · David L Russell-Jones · 2006 · 565 citations · Cited by this paper
  19. Sodium Butyrate Attenuates Renal Fibrosis by Regulating Glycolysis and Histone H4K12 Lactylation in Diabetic Kidney Disease · 2026 · Related
  20. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial · Bo Åhrén · 2017 · 492 citations · Cited by this paper
  21. Methodological and Conceptual Concerns Regarding the 24‐h Glycaemia/C‐Peptide Ratio as a Novel Insulin Sensitivity Index · 2026 · Related
  22. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial · Vanita R. Aroda · 2017 · 460 citations · Cited by this paper
  23. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial · Helena W. Rodbard · 2018 · 410 citations · Cited by this paper
  24. Identification of barriers to insulin therapy and approaches to overcoming them · David L Russell-Jones · 2017 · 239 citations · Cited by this paper
  25. Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species · Lene Jensen · 2017 · 179 citations · Cited by this paper
  26. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin · Julio Rosenstock · 2023 · 164 citations · Cited by this paper
  27. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial · Chantal Mathieu · 2023 · 146 citations · Cited by this paper
  28. Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes · Ildiko Lingvay · 2023 · 144 citations · Cited by this paper
  29. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial · Athena Philis‐Tsimikas · 2023 · 141 citations · Cited by this paper
  30. Pharmacokinetics and Tolerability of a Single Dose of Semaglutide, a Human Glucagon-Like Peptide-1 Analog, in Subjects With and Without Renal Impairment · Thomas C Marbury · 2017 · 128 citations · Cited by this paper
  31. Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) · HARPREET SINGH BAJAJ · 2023 · 94 citations · Cited by this paper
  32. Pharmacokinetics and tolerability of semaglutide in people with hepatic impairment · Lene Jensen · 2017 · 75 citations · Cited by this paper
  33. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Denmark/Sweden multicentre, prospective, observational study · Neda Rajamand Ekberg · 2021 · 62 citations · Cited by this paper
  34. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups · Jean‐François Yale · 2022 · 51 citations · Cited by this paper
  35. Integrating liver endpoints in clinical trials of cardiovascular and kidney disease · Faiez M. Zannad · 2024 · 42 citations · Cited by this paper
  36. Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials · Carmine Zoccali · 2019 · 37 citations · Cited by this paper
  37. Insulin Icodec Weekly: A Basal Insulin Analogue for Type 2 Diabetes · HARPREET SINGH BAJAJ · 2023 · 27 citations · Cited by this paper
  38. Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial · Ildiko Lingvay · 2025 · 27 citations · Cited by this paper
  39. Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial · Chantal Mathieu · 2025 · 25 citations · Cited by this paper

Source: OpenAlex (CC0)